Aurobindo Pharma’s CuraTeQ Biologics to invest around Rs 300 Cr for capacity expansion
The board also approved entering into CMO for biologicals for effective utilisation of capacities
Aurobindo Pharma announced that CuraTeQ Biologics is planning to invest around Rs 300 crore in the capacity expansion of biologics manufacturing facilities.
According to a PTI report, the board of directors of CuraTeQ Biologics at its recently held meeting approved the expansion of its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to future requirements, Aurobindo Pharma said in a regulatory filing.
“The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore,” it said, adding that the facility is likely to be fully operational by FY26.
Further, the board also approved entering into contract manufacturing operations (CMO) for biologicals for effective utilisation of capacities.
The company further said the board of its other wholly-owned subsidiary, Auro Vaccines, has also approved exploring possibilities to offer contract manufacturing services to global vaccine developers to effectively utilise its existing manufacturing capacity.
